secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001823239-24-000093
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance
--------------------------------------------------------------------------------

- Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.
- Net loss $(14.5)M vs $(11.9)M prior year; Adjusted EBITDA $16.9M up from $9.1M.
- H1 2024 revenue $137.6M (-7% YoY); net loss $(37.2)M vs $(13.3)M.
- Reaffirms FY2024 revenue guidance $265M-$285M.
- Business updates: TriLink-Johns Hopkins collaboration, Flanders facilities milestones, new product launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000093/0001823239-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000093/mrvi-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001823239-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer